Compounding Pharmacies Market - Global Compounding Pharmacies Industry Analysis, Size, Share, Growth, Trends, and Forecast 2025-2032 - (By Dosage Form, By Patient Group, By Therapeutic Area, By Sterility, By Geographic Coverage and By Company)

Description

The global Compounding Pharmacies Market is projected to be valued at USD 10 billion in 2025 and expected to reach USD 13.9 billion by 2032, expanding at a CAGR of 4.8% during the forecast period. Compounding pharmacies-specialized facilities that create customized medications tailored to individual patient needs-are gaining strong traction worldwide as personalized medicine becomes a core pillar of modern healthcare. The industry is witnessing transformative shifts driven by demographic trends, drug shortages, and rising consumer preference for patient-specific formulations.

Market Insights

The compounding pharmacy industry represents a critical segment bridging conventional pharmaceutical production and personalized treatment models. The sector is expanding as healthcare systems prioritize flexibility in dosage, allergy-friendly alternatives, and discontinued drug recreation. Key innovations in sterile compounding, automation, and regulatory compliance are reinforcing patient safety and improving efficiency. Moreover, the growing burden of chronic conditions and the need for specialized pediatric and geriatric formulations underscore the market's resilience.

Hospitals, specialty clinics, and independent pharmacies are increasingly partnering with compounding facilities to deliver tailored dosage forms-capsules, gels, suspensions, and injectables-aligned with patient profiles. This synergy supports treatment adherence, minimizes side effects, and fills therapeutic gaps unaddressed by mass-produced pharmaceuticals.

Key Market Drivers

Personalized Medicine Revolution: Growing demand for individualized therapies is the single biggest driver for compounding pharmacies. Patients with rare diseases or allergies benefit from customized drug combinations and strengths unavailable in commercial forms.
Rising Geriatric and Pediatric Populations: Older adults and children often require dosage adjustments or non-standard formulations, fueling prescription compounding services globally.
Drug Shortages and Recalls: Periodic shortages of essential medicines are pushing hospitals and clinics toward compounding alternatives to ensure treatment continuity.
Technological Advancements: Integration of robotics, sterile compounding systems, and automated quality checks enhances precision and compliance with USP <797> and <800> standards.
Chronic Disease Prevalence: With escalating cases of diabetes, cardiovascular diseases, and hormonal disorders, demand for compounded bioidentical hormones and pain management therapies is accelerating.

Business Opportunity

The compounding pharmacies market offers a lucrative growth frontier for investors and healthcare providers alike. Expansion opportunities lie in niche sectors such as bioidentical hormone replacement therapy (BHRT), veterinary compounding, and nutraceutical formulations. Furthermore, regulatory frameworks in regions such as North America and Europe are evolving to balance innovation with safety, promoting trust in compounded medications.

Independent compounding facilities are increasingly adopting pharmacy management software, AI-based formulation tracking, and blockchain-based supply transparency, opening new possibilities for efficiency and patient engagement. Partnerships between compounding pharmacists and healthcare providers also create a seamless continuum of care, bridging clinical and compounding expertise for enhanced patient outcomes.

Regional Analysis

North America remains the leading region in the compounding pharmacies industry, supported by advanced healthcare infrastructure, regulatory clarity from the U.S. FDA and the Pharmacy Compounding Accreditation Board (PCAB), and a robust network of independent pharmacies. The U.S. market's growth is strengthened by the continued shortage of key drugs and the expanding adoption of customized therapies in oncology, hormone treatment, and dermatology.

Europe follows closely, with Germany, the U.K., and France focusing on compounding for hospital-based care and pediatric formulations. Regulatory alignment under EMA and country-specific pharmacy acts ensures safety and quality assurance.

Asia Pacific is emerging as the fastest-growing region, propelled by rising healthcare spending, modernization of pharmacies, and the rising acceptance of compounding among urban populations in India, Japan, and Australia. Technological adoption and growing awareness about patient-centric care further amplify regional opportunities.

Latin America and the Middle East & Africa markets are steadily expanding as governments strengthen pharmaceutical regulations and hospital compounding capabilities to overcome import dependencies.

Key Players

The competitive landscape is moderately fragmented, with global and regional players emphasizing product safety, quality control, and regulatory compliance. Prominent market participants include:

Fagron
B. Braun Melsungen AG
Dougherty's Pharmacy, Inc.
Pencol Compounding Pharmacy
Wedgewood Pharmacy
Fresenius Kabi AG
Advanced Pharmacy
Institutional Pharmacy Solutions
Cantrell Drug Company
Triangle Compounding Pharmacy

These companies are investing in advanced facilities, expanding sterile compounding units, and engaging in mergers to strengthen regional presence and service portfolios.

Segmentation

By Product:

Oral Medications
Topical Medications
Injectable Medications
Nasal Medications
Ophthalmic Medications

By Application:

Pain Management
Hormone Replacement Therapy (HRT)
Dermatology
Pediatric
Geriatric
Veterinary
Others

By Sterility:

Sterile Compounding
Non-Sterile Compounding

By End User:

Hospitals
Specialty Clinics
Retail Pharmacies
Homecare Settings

By Region:

North America
Europe
Asia Pacific
Latin America
Middle East & Africa

1. Executive Summary

1.1. Global Compounding Pharmacies Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2025
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. COVID-19 Impact Analysis
2.5. Porter's Fiver Forces Analysis
2.6. Impact of Russia-Ukraine Conflict
2.7. PESTLE Analysis
2.8. Regulatory Analysis
2.9. Price Trend Analysis
- 2.9.1. Current Prices and Future Projections, 2024-2032
- 2.9.2. Price Impact Factors

3. Global Compounding Pharmacies Market Outlook, 2019 - 2032

3.1. Global Compounding Pharmacies Market Outlook, by Dosage Form, Value (US$ Bn), 2019-2032
- 3.1.1. Oral
- 3.1.2. Topical
- 3.1.3. Parenteral
- 3.1.4. Rectal
- 3.1.5. Others
3.2. Global Compounding Pharmacies Market Outlook, by Patient Group, Value (US$ Bn), 2019-2032
- 3.2.1. Pediatric
- 3.2.2. Geriatric
- 3.2.3. Adult
- 3.2.4. Veterinary
3.3. Global Compounding Pharmacies Market Outlook, by Therapeutic Area, Value (US$ Bn), 2019-2032
- 3.3.1. Pain management
- 3.3.2. Hormone replacement therapy (BHRT)
- 3.3.3. Dermatology
- 3.3.4. Gastroenterology
- 3.3.5. Others
3.4. Global Compounding Pharmacies Market Outlook, by Sterility, Value (US$ Bn), 2019-2032
- 3.4.1. Sterile
- 3.4.2. Non-Sterile
3.5. Global Compounding Pharmacies Market Outlook, by Region, Value (US$ Bn), 2019-2032
- 3.5.1. North America
- 3.5.2. Europe
- 3.5.3. Asia Pacific
- 3.5.4. Latin America
- 3.5.5. Middle East & Africa

4. North America Compounding Pharmacies Market Outlook, 2019 - 2032

4.1. North America Compounding Pharmacies Market Outlook, by Dosage Form, Value (US$ Bn), 2019-2032
- 4.1.1. Oral
- 4.1.2. Topical
- 4.1.3. Parenteral
- 4.1.4. Rectal
- 4.1.5. Others
4.2. North America Compounding Pharmacies Market Outlook, by Patient Group, Value (US$ Bn), 2019-2032
- 4.2.1. Pediatric
- 4.2.2. Geriatric
- 4.2.3. Adult
- 4.2.4. Veterinary
4.3. North America Compounding Pharmacies Market Outlook, by Therapeutic Area, Value (US$ Bn), 2019-2032
- 4.3.1. Pain management
- 4.3.2. Hormone replacement therapy (BHRT)
- 4.3.3. Dermatology
- 4.3.4. Gastroenterology
- 4.3.5. Others
4.4. North America Compounding Pharmacies Market Outlook, by Sterility, Value (US$ Bn), 2019-2032
- 4.4.1. Sterile
- 4.4.2. Non-Sterile
4.5. North America Compounding Pharmacies Market Outlook, by Country, Value (US$ Bn), 2019-2032
- 4.5.1. U.S. Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
- 4.5.2. U.S. Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
- 4.5.3. U.S. Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
- 4.5.4. U.S. Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
- 4.5.5. Canada Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
- 4.5.6. Canada Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
- 4.5.7. Canada Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
- 4.5.8. Canada Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
4.6. BPS Analysis/Market Attractiveness Analysis

5. Europe Compounding Pharmacies Market Outlook, 2019 - 2032

5.1. Europe Compounding Pharmacies Market Outlook, by Dosage Form, Value (US$ Bn), 2019-2032
- 5.1.1. Oral
- 5.1.2. Topical
- 5.1.3. Parenteral
- 5.1.4. Rectal
- 5.1.5. Others
5.2. Europe Compounding Pharmacies Market Outlook, by Patient Group, Value (US$ Bn), 2019-2032
- 5.2.1. Pediatric
- 5.2.2. Geriatric
- 5.2.3. Adult
- 5.2.4. Veterinary
5.3. Europe Compounding Pharmacies Market Outlook, by Therapeutic Area, Value (US$ Bn), 2019-2032
- 5.3.1. Pain management
- 5.3.2. Hormone replacement therapy (BHRT)
- 5.3.3. Dermatology
- 5.3.4. Gastroenterology
- 5.3.5. Others
5.4. Europe Compounding Pharmacies Market Outlook, by Sterility, Value (US$ Bn), 2019-2032
- 5.4.1. Sterile
- 5.4.2. Non-Sterile
5.5. Europe Compounding Pharmacies Market Outlook, by Country, Value (US$ Bn), 2019-2032
- 5.5.1. Germany Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
- 5.5.2. Germany Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
- 5.5.3. Germany Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
- 5.5.4. Germany Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
- 5.5.5. Italy Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
- 5.5.6. Italy Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
- 5.5.7. Italy Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
- 5.5.8. Italy Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
- 5.5.9. France Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
- 5.5.10. France Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
- 5.5.11. France Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
- 5.5.12. France Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
- 5.5.13. U.K. Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
- 5.5.14. U.K. Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
- 5.5.15. U.K. Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
- 5.5.16. U.K. Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
- 5.5.17. Spain Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
- 5.5.18. Spain Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
- 5.5.19. Spain Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
- 5.5.20. Spain Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
- 5.5.21. Russia Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
- 5.5.22. Russia Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
- 5.5.23. Russia Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
- 5.5.24. Russia Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
- 5.5.25. Rest of Europe Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
- 5.5.26. Rest of Europe Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
- 5.5.27. Rest of Europe Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
- 5.5.28. Rest of Europe Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
5.6. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Compounding Pharmacies Market Outlook, 2019 - 2032

6.1. Asia Pacific Compounding Pharmacies Market Outlook, by Dosage Form, Value (US$ Bn), 2019-2032
- 6.1.1. Oral
- 6.1.2. Topical
- 6.1.3. Parenteral
- 6.1.4. Rectal
- 6.1.5. Others
6.2. Asia Pacific Compounding Pharmacies Market Outlook, by Patient Group, Value (US$ Bn), 2019-2032
- 6.2.1. Pediatric
- 6.2.2. Geriatric
- 6.2.3. Adult
- 6.2.4. Veterinary
6.3. Asia Pacific Compounding Pharmacies Market Outlook, by Therapeutic Area, Value (US$ Bn), 2019-2032
- 6.3.1. Pain management
- 6.3.2. Hormone replacement therapy (BHRT)
- 6.3.3. Dermatology
- 6.3.4. Gastroenterology
- 6.3.5. Others
6.4. Asia Pacific Compounding Pharmacies Market Outlook, by Sterility, Value (US$ Bn), 2019-2032
- 6.4.1. Sterile
- 6.4.2. Non-Sterile
6.5. Asia Pacific Compounding Pharmacies Market Outlook, by Country, Value (US$ Bn), 2019-2032
- 6.5.1. China Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
- 6.5.2. China Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
- 6.5.3. China Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
- 6.5.4. China Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
- 6.5.5. Japan Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
- 6.5.6. Japan Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
- 6.5.7. Japan Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
- 6.5.8. Japan Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
- 6.5.9. South Korea Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
- 6.5.10. South Korea Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
- 6.5.11. South Korea Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
- 6.5.12. South Korea Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
- 6.5.13. India Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
- 6.5.14. India Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
- 6.5.15. India Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
- 6.5.16. India Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
- 6.5.17. Southeast Asia Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
- 6.5.18. Southeast Asia Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
- 6.5.19. Southeast Asia Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
- 6.5.20. Southeast Asia Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
- 6.5.21. Rest of SAO Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
- 6.5.22. Rest of SAO Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
- 6.5.23. Rest of SAO Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
- 6.5.24. Rest of SAO Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
6.6. BPS Analysis/Market Attractiveness Analysis

7. Latin America Compounding Pharmacies Market Outlook, 2019 - 2032

7.1. Latin America Compounding Pharmacies Market Outlook, by Dosage Form, Value (US$ Bn), 2019-2032
- 7.1.1. Oral
- 7.1.2. Topical
- 7.1.3. Parenteral
- 7.1.4. Rectal
- 7.1.5. Others
7.2. Latin America Compounding Pharmacies Market Outlook, by Patient Group, Value (US$ Bn), 2019-2032
- 7.2.1. Pediatric
- 7.2.2. Geriatric
- 7.2.3. Adult
- 7.2.4. Veterinary
7.3. Latin America Compounding Pharmacies Market Outlook, by Therapeutic Area, Value (US$ Bn), 2019-2032
- 7.3.1. Pain management
- 7.3.2. Hormone replacement therapy (BHRT)
- 7.3.3. Dermatology
- 7.3.4. Gastroenterology
- 7.3.5. Others
7.4. Latin America Compounding Pharmacies Market Outlook, by Sterility, Value (US$ Bn), 2019-2032
- 7.4.1. Sterile
- 7.4.2. Non-Sterile
7.5. Latin America Compounding Pharmacies Market Outlook, by Country, Value (US$ Bn), 2019-2032
- 7.5.1. Brazil Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
- 7.5.2. Brazil Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
- 7.5.3. Brazil Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
- 7.5.4. Brazil Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
- 7.5.5. Mexico Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
- 7.5.6. Mexico Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
- 7.5.7. Mexico Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
- 7.5.8. Mexico Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
- 7.5.9. Argentina Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
- 7.5.10. Argentina Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
- 7.5.11. Argentina Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
- 7.5.12. Argentina Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
- 7.5.13. Rest of LATAM Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
- 7.5.14. Rest of LATAM Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
- 7.5.15. Rest of LATAM Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
- 7.5.16. Rest of LATAM Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
7.6. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Compounding Pharmacies Market Outlook, 2019 - 2032

8.1. Middle East & Africa Compounding Pharmacies Market Outlook, by Dosage Form, Value (US$ Bn), 2019-2032
- 8.1.1. Oral
- 8.1.2. Topical
- 8.1.3. Parenteral
- 8.1.4. Rectal
- 8.1.5. Others
8.2. Middle East & Africa Compounding Pharmacies Market Outlook, by Patient Group, Value (US$ Bn), 2019-2032
- 8.2.1. Pediatric
- 8.2.2. Geriatric
- 8.2.3. Adult
- 8.2.4. Veterinary
8.3. Middle East & Africa Compounding Pharmacies Market Outlook, by Therapeutic Area, Value (US$ Bn), 2019-2032
- 8.3.1. Pain management
- 8.3.2. Hormone replacement therapy (BHRT)
- 8.3.3. Dermatology
- 8.3.4. Gastroenterology
- 8.3.5. Others
8.4. Middle East & Africa Compounding Pharmacies Market Outlook, by Sterility, Value (US$ Bn), 2019-2032
- 8.4.1. Sterile
- 8.4.2. Non-Sterile
8.5. Middle East & Africa Compounding Pharmacies Market Outlook, by Country, Value (US$ Bn), 2019-2032
- 8.5.1. GCC Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
- 8.5.2. GCC Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
- 8.5.3. GCC Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
- 8.5.4. GCC Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
- 8.5.5. South Africa Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
- 8.5.6. South Africa Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
- 8.5.7. South Africa Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
- 8.5.8. South Africa Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
- 8.5.9. Egypt Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
- 8.5.10. Egypt Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
- 8.5.11. Egypt Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
- 8.5.12. Egypt Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
- 8.5.13. Nigeria Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
- 8.5.14. Nigeria Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
- 8.5.15. Nigeria Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
- 8.5.16. Nigeria Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
- 8.5.17. Rest of Middle East Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
- 8.5.18. Rest of Middle East Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
- 8.5.19. Rest of Middle East Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
- 8.5.20. Rest of Middle East Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
8.6. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. Company Vs Segment Heatmap
9.2. Company Market Share Analysis, 2024
9.3. Competitive Dashboard
9.4. Company Profiles
- 9.4.1. Walgreens Co.
  - 9.4.1.1. Company Overview
  - 9.4.1.2. Product Portfolio
  - 9.4.1.3. Financial Overview
  - 9.4.1.4. Business Strategies and Developments
- 9.4.2. Fagron
  - 9.4.2.1. Company Overview
  - 9.4.2.2. Product Portfolio
  - 9.4.2.3. Financial Overview
  - 9.4.2.4. Business Strategies and Developments
- 9.4.3. B. Braun
  - 9.4.3.1. Company Overview
  - 9.4.3.2. Product Portfolio
  - 9.4.3.3. Financial Overview
  - 9.4.3.4. Business Strategies and Developments
- 9.4.4. Fresenius Kabi
  - 9.4.4.1. Company Overview
  - 9.4.4.2. Product Portfolio
  - 9.4.4.3. Financial Overview
  - 9.4.4.4. Business Strategies and Developments
- 9.4.5. Clinigen Group
  - 9.4.5.1. Company Overview
  - 9.4.5.2. Product Portfolio
  - 9.4.5.3. Financial Overview
  - 9.4.5.4. Business Strategies and Developments
- 9.4.6. Wedgewood Pharmacy
  - 9.4.6.1. Company Overview
  - 9.4.6.2. Product Portfolio
  - 9.4.6.3. Financial Overview
  - 9.4.6.4. Business Strategies and Developments
- 9.4.7. Avella Specialty Pharmacy
  - 9.4.7.1. Company Overview
  - 9.4.7.2. Product Portfolio
  - 9.4.7.3. Financial Overview
  - 9.4.7.4. Business Strategies and Developments
- 9.4.8. Triangle Compounding Pharmacy
  - 9.4.8.1. Company Overview
  - 9.4.8.2. Product Portfolio
  - 9.4.8.3. Financial Overview
  - 9.4.8.4. Business Strategies and Developments
- 9.4.9. Pencol Compounding Pharmacy
  - 9.4.9.1. Company Overview
  - 9.4.9.2. Product Portfolio
  - 9.4.9.3. Financial Overview
  - 9.4.9.4. Business Strategies and Developments
- 9.4.10. US Compounding Inc.
  - 9.4.10.1. Company Overview
  - 9.4.10.2. Product Portfolio
  - 9.4.10.3. Financial Overview
  - 9.4.10.4. Business Strategies and Developments

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations